Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03361865
Title Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation

ureter transitional cell carcinoma

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma


Epacadostat + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.